Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus low-dose interferon alfa-2a in first-line metastatic clear cell renal cell carcinoma
2007-006611-23Phase 2Completed
- Sponsor
- Roche
- Start
- Sep 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and interferon alfa-2a in clear cell renal cell carcinoma (ccRCC) and metastatic renal cell carcinoma (mRCC), sponsored by Roche. Primary endpoints: Progression-free survival and Safety. Started Sep 2008; status: completed.
02
Drugs
bevacizumabinterferon alfa-2a
03
Conditions
clear cell renal cell carcinoma (ccRCC)metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2007-006611-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006611-23.